Development of a novel Dengue-1 virus replicon system expressing secretory Gaussia luciferase for analysis of viral replication and discovery of antiviral drugs

Jpn J Infect Dis. 2014;67(3):209-12. doi: 10.7883/yoken.67.209.

Abstract

Replicon systems have been used for high-throughput screening of anti-dengue virus (anti-DENV) inhibitors and for understanding mechanisms of viral replication. In the present study, we constructed novel DENV-1 replicons encoding Gaussia luciferase that was secreted into the culture medium. Two types of constructs were generated: RNA-based and DNA-based. Each type was translated in an internal ribosome entry site (IRES)-dependent or IRES-independent manner. Among these constructs, the DNA-based replicon employing IRES-dependent translation (DGL2) produced the highest titer. Luciferase levels in the culture medium revealed that the DGL2 replicon was inhibited by ribavirin (a well-known DENV inhibitor) at levels similar to those measured for drug inhibition of multi-round DENV-1 infection. These results indicate that the DNA-based IRES-driven DENV-1 replicon may facilitate studies on viral replication and antiviral compound discovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Cricetinae
  • Dengue / drug therapy
  • Dengue / virology
  • Dengue Virus / drug effects
  • Dengue Virus / genetics*
  • Drug Discovery / methods*
  • Genes, Reporter
  • Luciferases / genetics*
  • Luciferases / metabolism
  • RNA, Viral / genetics
  • Replicon / genetics*
  • Ribavirin / pharmacology
  • Virus Cultivation
  • Virus Replication / drug effects*
  • Virus Replication / genetics

Substances

  • Antiviral Agents
  • RNA, Viral
  • Ribavirin
  • Luciferases